Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD.
Isabell BrikellTheresa WimberleyClara AlbiñanaEmil Michael PedersenBjarni Jóhann VilhjálmssonEsben AgerboDitte DemontisAnders D BørglumAndrew J SchorkSonja LaBiancaThomas WergeOle MorsDavid M HougaardAnita ThaparPreben Bo MortensenSøren DalsgaardPublished in: The American journal of psychiatry (2021)
The study findings suggest that individuals with ADHD with higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have a higher risk for stimulant treatment discontinuation and switch to nonstimulants. Despite the study's limited sample size, one putative GWAS hit for switch was identified, illustrating the potential of utilizing genomics linked to prescription databases to advance ADHD pharmacogenomics.
Keyphrases
- attention deficit hyperactivity disorder
- autism spectrum disorder
- working memory
- bipolar disorder
- mental health
- emergency department
- single cell
- genome wide
- depressive symptoms
- physical activity
- risk assessment
- sleep quality
- copy number
- adverse drug
- dna methylation
- artificial intelligence
- replacement therapy
- smoking cessation